

研究成果の刊行に関する一覧表

雑誌

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Migita K, Nakamura M, Abiru S, Jiuchi Y, Nagaoka S, Komori A, Hashimoto S, Bekki S, Yamasaki K, <u>Komatsu T</u> , Shimada M, <u>Kouno H</u> , <u>Hijioka T</u> , Kohjima M, <u>Nakamuta M</u> , Kato M, Yoshizawa K, <u>Ohta H</u> , Nakamura Y, Takezaki E, Nishimura H, <u>Sato T</u> , Ario K, Hirashima N, Oohara Y, Naganuma A, <u>Muro T</u> , Sakai H, <u>Mita E</u> , <u>Sugi K</u> , Yamashita H, Makita F, <u>Yatsushashi H</u> , Ishibashi H, Yasunami M.	Association of STAT4 Polymorphisms with Susceptibility to Type-1 Autoimmune Hepatitis in the Japanese Population.	PLoS One.	8(8)	e71382	2013
Aiba Y, Harada K, Komori A, Ito M, Shimoda S, Nakamura H, Nagaoka S, Abiru S, Migita K, Ishibashi H, Nakanuma Y, Nishida N, Kawashima M, Tokunaga K, <u>Yatsushashi H</u> , Nakamura M.	Systemic and local expression levels of TNF-like ligand 1A and its decoy receptor 3 are increased in primary biliary cirrhosis.	Liver Int.			2013
Inamine T, Higa S, Noguchi F, Kondo S, Omagari K, <u>Yatsushashi H</u> , Tsukamoto K, Nakamura M.	Association of genes involved in bile acid synthesis with the progression of primary biliary cirrhosis in Japanese patients.	J Gastroenterol Hepatol.	48(10)	1160-70	2013
Fujino T, Aoyagi Y, Takahashi M, Yada R, Yamamoto N, Ohishi Y, Nishiura A, Kohjima M, Yoshimoto T, Fukuizumi K, Nakashima M, Kato M, Kotoh K, <u>Nakamuta M</u> , Enjoji M.	Association of ITPA polymorphism with outcomes of peginterferon- α plus ribavirin combination therapy.	World J Gastrointest Pharmacol Ther.	4(3)	54-60	2013
Ogawa E, Furusyo N, <u>Nakamuta M</u> , Kajiwara E, Nomura H, Dohmen K, Takahashi K, Satoh T, Azuma K, Kawano A, Tanabe Y, Kotoh K, Shimoda S, Hayashi J; Kyushu University Liver Disease Study (KULDS) Group.	Clinical milestones for the prediction of severe anemia by chronic hepatitis C patients receiving telaprevir-based triple therapy.	J Hepatol.	59(4)	667-74	2013

Furusyo N, Ogawa E, <u>Nakamuta M</u> , Kajiwara E, Nomura H, Dohmen K, Takahashi K, Satoh T, Azuma K, Kawano A, Tanabe Y, Kotoh K, Shimoda S, Hayashi J; Kyushu University Liver Disease Study (KULDS) Group.	Telaprevir can be successfully and safely used to treat older patients with genotype 1b chronic hepatitis C.	J Hepatol.	59(2)	205-12	2013
Ogawa E, Furusyo N, Kajiwara E, Takahashi K, Nomura H, Maruyama T, Tanabe Y, Satoh T, <u>Nakamuta M</u> , Kotoh K, Azuma K, Dohmen K, Shimoda S, Hayashi J; Kyushu University Liver Disease Study (KULDS) Group.	Efficacy of pegylated interferon alpha-2b and ribavirin treatment on the risk of hepatocellular carcinoma in patients with chronic hepatitis C: a prospective, multicenter study.	J Hepatol.	58(3)	495-501	2013
Yokoyama S, Takahashi S, Kawakami Y, C. Nelson Hayes, <u>Kohno H</u> , Kohno H, Tsuji K, Aisaka Y, Kira S, Yamashina K, Nonaka M, Moriya T, Kitamoto M, Aimitsu S, Nakanishi T, Kawakami H, Chayama K.	Effect of vitamin D supplementation on pegylated interferon/ribavirin therapy for chronic hepatitis C genotype 1b: A randomized controlled trial.	J Viral Hepatitis.			
Ito K, Yotsuyanagi H, <u>Yatsunami H</u> , Karino Y, Takikawa Y, Saito T, Arase Y, Imazeki F, Kurosaki M, Umemura T, Ichida T, Toyoda H, Yoneda M, <u>Mita E</u> , Yamamoto K, Michitaka K, Maeshiro T, Tanuma J, Tanaka Y, Sugiyama M, Murata K, <u>Masaki N</u> , Mizokami M; Japanese AHB Study Group.	Risk factors for long-term persistence of serum hepatitis B surface antigen following acute hepatitis B virus infection in Japanese adults.	Hepatology	59(1)	89-97	2014
正木尚彦 .	ウイルス肝炎に関する国の対策事業、公費助成や受診勧奨など . 特集 ウイルス肝炎の新展開	診断と治療	101(9)	1375-80	2013
正木尚彦 , 斎藤英胤 , 朝比奈靖浩 .	鼎談 : ウイルス性肝炎はまだなくなる .	成人病と生活習慣病	43(11)	1287-304	2013
平嶋 昇 , 小林慶子 , 高橋宏尚 , 喜田裕一 , 久野剛史 , 横井美咲 , 斎藤雅之 , 龍華庸光 , 都築智之 , 島田昌明 , 岩瀬弘明 .	原因不明のHBV再活性化を疑う高齢2症例 .	医療	67(2)	70-8	2013

Miyaaki H, Ichikawa T, Kamo Y, Taura N, Honda T, Shibata H, Milazzo M, Fornari F, Gramantieri L, Bolondi L, <u>Nakao K.</u>	Significance of serum and hepatic microRNA-122 levels in patients with non-alcoholic fatty liver disease.	Liver Int.			2013
Taura N, Ichikawa T, Miyaaki H, Ozawa E, Tsutsumi T, Tsuruta S, Kato Y, Goto T, Kinoshita N, Fukushima M, Kato H, Ohata K, Ohba K, Masuda J, Hamasaki K, <u>Yatsushiro H, Nakao K.</u>	Frequency of elevated biomarkers in patients with cryptogenic hepatocellular carcinoma.	Med Sci Monit.	19	742-50	2013
Matsuzaki T, Tatsuki I, Otani M, Akiyama M, Ozawa E, Miuma S, Miyaaki H, Taura N, Hayashi T, Okudaira S, Takatsuki M, Isomoto H, Takeshima F, Eguchi S, <u>Nakao K.</u>	Significance of hepatitis B virus core-related antigen and covalently closed circular DNA levels as markers of hepatitis B virus re-infection after liver transplantation.	J Gastroenterol Hepatol.	28(7)	1217-22	2013
<u>Nakao K.</u> , Ichikawa T.	Recent topics on α -fetoprotein.	Hepatol Res.	43(8)	820-5	2013
Xu K, Lee F, Gao SJ, Chung JE, <u>Yano H.</u> , Kurisawa M.	Injectable hyaluronic acid-tyramine hydrogels incorporating interferon-alpha2a for liver cancer therapy.	J Control Release.	166(3)	203-10	2013
Nakayama M, Ogasawara S, Akiba J, Ueda K, Koura K, Todoroki K, Kinoshita H, <u>Yano H.</u>	SP cell fractions from HCC cell lines increased with tumor dedifferentiation, but lack characteristic features of CSCs.	J Gastroenterol Hepatol.			2013
Kusano H, Ogasawara S, Akiba J, Nakayama M, Ueda K, <u>Yano H.</u>	Antiproliferative effects of sorafenib and pegylated IFNalpha2b on human liver cancer cells in vitro and in vivo.	Int J Oncol.	42(6)	1897-903	2013
Kusano H, Akiba J, Ogasawara S, Sanada S, Yasumoto M, Nakayama M, Ueda K, Kurita T, Todoroki K, Umeno Y, Nakashima O, <u>Yano H.</u>	Pegylated Interferon-alpha2a Inhibits Proliferation of Human Liver Cancer Cells In Vitro and In Vivo.	PLoS One.	8(12)	e83195	2013
Kondo R, Nakashima O, Sata M, Imazeki F, Yokosuka O, Tanikawa K, Kage M, <u>Yano H.</u>	Pathological characteristics of patients who develop hepatocellular carcinoma with negative results of both serous hepatitis B surface antigen and hepatitis C virus antibody.	Hepatol Res.			2013

Akiba J, Nakashima O, Hattori S, Tanikawa K, Takenaka M, Nakayama M, Kondo R, Nomura Y, Koura K, Ueda K, Sanada S, Naito Y, Yamaguchi R, <u>Yano H.</u>	Clinicopathologic analysis of combined hepatocellular-cholangiocarcinoma according to the latest WHO classification.	Am J Surg Pathol.	37(4)	496-505	2013
Bae SK, <u>Yatsuhashi H.</u> , Hashimoto S, Motoyoshi Y, Ozawa E, Nagaoka S, Abiru S, Komori A, Migita K, Nakamura M, Ito M, Miyakawa Y, Ishibashi H.	Prediction of early HBeAg seroconversion by decreased titers of HBeAg in the serum combined with increased grades of lobular inflammation in the liver.	Med Sci Monit.	18 (12)	CR698-705	2012
Watanabe T, Sugauchi F, Tanaka Y, Matsuura K, <u>Yatsuhashi H.</u> , Murakami S, Iijima S, Iio E, Sugiyama M, Shimada T, Kakuni M, Kohara M, Mizokami M.	Hepatitis C virus kinetics by administration of pegylated interferon in human and chimeric mice carrying human hepatocytes with variants of the IL28B gene.	Gut			2012
Izumi N, Asahina Y, Kurosaki M, Yamada G, Kawai T, Kajiwara E, Okamura Y, Takeuchi T, Yokosuka O, Kariyama K, Toyoda J, Inao M, Tanaka E, Moriwaki H, Adachi H, Katsushima S, Kudo M, Takaguchi K, Hiasa Y, Chayama K, <u>Yatsuhashi H.</u> , Oketani M, Kumada H.	Inhibition of hepatocellular carcinoma by PegIFN α -2a in patients with chronic hepatitis C: a nationwide multicenter cooperative study.	J Gastroenterol.			2012
Nakamura M, Nishida N, Kawashima M, Aiba Y, Tanaka A, Yasunami M, Nakamura H, Komori A, <u>Nakamuta M.</u> , Zeniya M, Hashimoto E, Ohira H, Yamamoto K, Onji M, Kaneko S, Honda M, Yamagiwa S, <u>Nakao K.</u> , Ichida T, Takikawa H, Seike M, Umemura T, Ueno Y, Sakisaka S, Kikuchi K, Ebinuma H, Yamashiki N, Tamura S, Sugawara Y, Mori A, Yagi S, Shirabe K, Taketomi A, Arai K, Monoe K, Ichikawa T, Taniai M, Miyake Y, Kumagi T, Abe M, Yoshizawa K, Joshita S, Shimoda S, Honda K, Takahashi H, Hirano K, Takeyama Y,	Genome-wide Association Study Identifies TNFSF15 and POU2AF1 as Susceptibility Loci for Primary Biliary Cirrhosis in the Japanese Population.	Am J Hum Genet.	91 (4)	721-8	2012

Harada K, Migita K, Ito M, <u>Yatsuhashi H</u> , Fukushima N, <u>Ota H</u> , <u>Komatsu T</u> , Saoshiro T, <u>Ishida J</u> , <u>Kouno H</u> , Kouno H, <u>Yagura M</u> , <u>Kobayashi M</u> , <u>Muro T</u> , <u>Masaki N</u> , <u>Hirata K</u> , Watanabe Y, Nakamura Y, <u>Shimada M</u> , Hirashima N, <u>Komeda T</u> , <u>Sugi K</u> , Koga M, Ario K, Takesaki E, Maehara Y, Uemoto S, Kokudo N, Tsubouchi H, Mizokami M, Nakanuma Y, Tokunaga K, Ishibashi H.					
Ueda T, Tsuchiya K, Hashimoto S, Inoue T, Inao M, Tanaka A, Kaito M, Imazaki F, Nishiguchi S, Mochida S, Yokosuka O, <u>Yatsuhashi H</u> , Izumi N, Kudo M, for the RETRY Study Group.	Retreatment with Peginterferon -2a + Ribavirin in Patients Who Failed Previous Peginterferon -2b + Ribavirin Combination Therapy.	Dig Dis.	30 (6)	554-60	2012
Migita K, Abiru S, Ohtani M, Jiuchi Y, Maeda Y, Bae SK, Bekki S, Hashimoto S, Yesmembetov K, Nagaoka S, Nakamura M, Komori A, Ichikawa T, <u>Nakao K</u> , <u>Yatsuhashi H</u> , Ishibashi H, Yasunami M.	HLA-DP gene polymorphisms and hepatitis B infection in the Japanese population.	Transl Res.	160 (6)	443-4	2012
Kani S, Tanaka Y, Matsuura K, Watanabe T, <u>Yatsuhashi H</u> , Orito E, Inose K, Motojuku N, Wakimoto Y, Mizokami M.	Development of new IL28B genotyping method using Invader Plus assay.	Microbiol Immunol.	56 (5)	318-23	2012
Migita K, Watanabe Y, Jiuchi Y, Nakamura Y, Saito A, <u>Yagura M</u> , <u>Ohta H</u> , <u>Shimada M</u> , <u>Mita E</u> , <u>Hijioka T</u> , Yamashita H, Takezaki E, <u>Muro T</u> , Sakai H, <u>Nakamuta M</u> , Abiru S, Komori A, Ito M, <u>Yatsuhashi H</u> , Nakamura M, Ishibashi H; the Japanese NHO-Liver-network study group.	Hepatocellular carcinoma and survival in patients with autoimmune hepatitis (Japanese National Hospital Organization-autoimmune hepatitis prospective study).	Liver Int.	32 (5)	837-44	2012

Kurosaki M, Hiramatsu N, Sakamoto M, Suzuki Y, Iwasaki M, Tamori A, Matsuura K, Kakinuma S, Sugauchi F, Sakamoto N, Nakagawa M, <u>Yatsuhashi H</u> , Izumi N.	Age and total ribavirin dose are independent predictors of relapse after interferon therapy in chronic hepatitis C revealed by data mining analysis.	Antivir Ther.	17 (1)	35-43	2012
Matsumoto A, Tanaka E, Suzuki Y, Kobayashi M, Tanaka Y, Shinkai N, Hige S, <u>Yatsuhashi H</u> , Nagaoka S, Chayama K, Tsuge M, Yokosuka O, Imazeki F, Nishiguchi S, Saito M, Fujiwara K, Torii N, Hiramatsu N, Karino Y, Kumada H.	Combination of hepatitis B viral antigens and DNA for prediction of relapse after discontinuation of nucleos(t)ide analogs in patients with chronic hepatitis B.	Hepatol Res.	42 (2)	139-49	2012
Kohjima M, Enjoji M, Yoshimoto T, Yada R, Fujino T, Aoyagi Y, Fukushima N, Fukuizumi K, Harada N, Yada M, Kato M, Kotoh K, Nakashima M, Sakamoto N, Tanaka Y, <u>Nakamuta M</u> .	Add-on therapy of pitavastatin and eicosapentaenoic acid improves outcome of peginterferon plus ribavirin treatment for chronic hepatitis C.	J Med Virol.	85 (2)	250-60	2013
Kotoh K, Fukushima M, Horikawa Y, Yamashita S, Kohjima M, <u>Nakamuta M</u> , Enjoji M.	Serum albumin is present at higher levels in alcoholic liver cirrhosis as compared to HCV-related cirrhosis.	Exp Ther Med.	3 (1)	72-5	2012
Enjoji M, Kohjima M, Kotoh K, <u>Nakamuta M</u> .	Metabolic disorders and steatosis in patients with chronic hepatitis C: metabolic strategies for antiviral treatments.	Int J Hepatol.			2012
Oze T, Hiramatsu N, <u>Mita E</u> , Akuta N, Sakamoto N, Nagano H, Itoh Y, Kaneko S, Izumi N, Nomura H, Hayashi N, Takehara T.	A multicenter survey of re-treatment with pegylated interferon plus ribavirin combination therapy for patients with chronic hepatitis C in Japan.	Hepatol Res.	43 (1)	35-43	2013
Higashitani K, Kanto T, Kuroda S, Yoshio S, Matsubara T, Kakita N, Oze T, Miyazaki M, Sakakibara M, Hiramatsu N, <u>Mita E</u> , Imai Y, Kasahara A, Okuno A, Takikawa O, Hayashi N, Takehara T.	Association of enhanced activity of indoleamine 2,3-dioxygenase in dendritic cells with the induction of regulatory T cells in chronic hepatitis C infection.	J Gastroenterol.	48(5)	660-70	2013

Harada N, Hiramatsu N, Oze T, Yamada R, Kurokawa M, Miyazaki M, Yakushijin T, Miyagi T, Tatsumi T, Kiso S, Kanto T, Kasahara A, Oshita M, <u>Mita E</u> , Hagiwara H, Inui Y, Katayama K, Tamura S, Yoshihara H, Imai Y, Inoue A, Hayashi N, Takehara T.	Incidence of hepatocellular carcinoma in HCV-infected patients with normal alanine aminotransferase levels categorized by Japanese treatment guidelines.	J Gastroenterol.	48(4)	535-43	2013
Nishida N, Sawai H, Matsuura K, Sugiyama M, Ahn SH, Park JY, Hige S, Kang JH, Suzuki K, Kurosaki M, Asahina Y, Mochida S, Watanabe M, Tanaka E, Honda M, Kaneko S, Orito E, Itoh Y, <u>Mita E</u> , Tamori A, Murawaki Y, Hiasa Y, Sakaida I, Korenaga M, Hino K, Ide T, Kawashima M, Mawatari Y, Sageshima M, Ogasawara Y, Koike A, Izumi N, Han KH, Tanaka Y, Tokunaga K, Mizokami M.	Genome-wide association study confirming association of HLA-DP with protection against chronic hepatitis B and viral clearance in Japanese and Korean.	PLoS One.	7 (6)		2012
Sawai H, Nishida N, Mbarek H, Matsuda K, Mawatari Y, Yamaoka M, Hige S, Kang JH, Abe K, Mochida S, Watanabe M, Kurosaki M, Asahina Y, Izumi N, Honda M, Kaneko S, Tanaka E, Matsuura K, Itoh Y, <u>Mita E</u> , Korenaga M, Hino K, Murawaki Y, Hiasa Y, Ide T, Ito K, Sugiyama M, Ahn SH, Han KH, Park JY, Yuen MF, Nakamura Y, Tanaka Y, Mizokami M, Tokunaga K.	No association for Chinese HBV-related hepatocellular carcinoma susceptibility SNP in other East Asian populations.	BMC Med Genet.	13		2012
Toyama T, Ishida H, Ishibashi H, <u>Yatsuhashi H</u> , <u>Nakamuta M</u> , <u>Shimada M</u> , <u>Ohta H</u> , <u>Satoh T</u> , Kato M, <u>Hijioka T</u> , Takano H, <u>Komeda T</u> , <u>Yagura M</u> , Mano H, Watanabe Y, <u>Kobayashi M</u> , <u>Mita E</u> .	Long-term outcomes of add-on adefovir dipivoxil therapy to ongoing lamivudine in patients with lamivudine-resistant chronic hepatitis B.	Hepatol Res.	42 (12)	1168-74	2012

坂根貞嗣、榊原祐子、由雄敏之、中水流正一、外山隆、石田 永、 <u>三田英治</u>	Telaprevir/Peg-IFN- 2b/Ribavirin併用療法導入直後の腎機能低下機序に関する検討 .	肝臓	53 (7)	434-5	2012
Takaguchi K, Moriwaki H, Doyama H, Iida M, <u>Yagura M</u> , Shimada N, Kang M, Yamada H, Kumada H.	Effects of branched-chain amino acid granules on serum albumin level and prognosis are dependent on treatment adherence in patients with liver cirrhosis.	Hepatol Res.			2012
<u>正木尚彦</u> .	肝炎をめぐる医療政策 .	医学のあゆみ	240 (12)	997-9	2012
Miyagi Y, Nomura H, Yamashita N, Tanimoto H, Ito K, <u>Masaki N</u> , Mizokami M, Shibuya T.	Estimation of two real-time RT-PCR assays for quantitation of hepatitis C virus RNA during PEG-IFN plus ribavirin therapy by HCV genotypes and IL28B genotype.	J Infect Chemother.	19 (1)	63-9	2013
Saito H, Ito K, Sugiyama M, Matsui T, Aoki Y, Imamura M, Murata K, <u>Masaki N</u> , Nomura H, Adachi H, Hige S, Enomoto N, Sakamoto N, Kurosaki M, Mizokami M, Watanabe S.	Factors responsible for the discrepancy between IL28B polymorphism prediction and the viral response to peginterferon plus ribavirin therapy in Japanese chronic hepatitis C patients.	Hepatol Res.	42 (10)	958-65	2012
Ito K, Kuno A, Ikehara Y, Sugiyama M, Saito H, Aoki Y, Matsui T, Imamura M, Korenaga M, Murata K, <u>Masaki N</u> , Tanaka Y, Hige S, Izumi N, Kurosaki M, Nishiguchi S, Sakamoto M, Kage M, Narimatsu H, Mizokami M.	LecT-Hepa, a glyco-marker derived from multiple lectins, as a predictor of liver fibrosis in chronic hepatitis C patients.	Hepatology	56 (4)	1448-56	2012
Nomura H, Miyagi Y, Tanimoto H, Yamashita N, Ito K, <u>Masaki N</u> , Mizokami M.	Increase in platelet count based on inosine triphosphatase genotype during interferon beta plus ribavirin combination therapy.	J Gastroenterol Hepatol.	27 (9)	1461-6	2012
都築智之, 岩瀬弘明, 島田昌明, 平嶋 昇, 日比野祐介, 龍華庸光, 齋藤雅之, 玉置 大, 神谷麻子, 横井美咲, 横幕能行, 藤崎誠一郎, 杉浦 互, 後藤秀実 .	当院におけるHIV ,HCV重複感染症例に対するペグインターフェロン, リバビリン併用療法の治療成績 .	日本消化器病学会雑誌	109 (7)	1186-96	2012
<u>杉 和洋</u> .	クリティカルパスを活用した肝臓病チーム医療の実践 .	Medical QOL		26-9	2013

Matsuzaki T, Ichikawa T, Kondo H, Taura N, Miyaaki H, Isomoto H, Takeshima F, <u>Nakao K.</u>	Prevalence of restless legs syndrome in Japanese patients with chronic liver disease.	Hepatol Res.	42 (12)	1221-6	2012
Miuma S, Ichikawa T, Arima K, Takeshita S, Muraoka T, Matsuzaki T, Ootani M, Shibata H, Akiyama M, Ozawa E, Miyaaki H, Taura N, Takeshima F, <u>Nakao K.</u>	Branched-chain amino acid deficiency stabilizes insulin-induced vascular endothelial growth factor mRNA in hepatocellular carcinoma cells.	J Cell Biochem.	113 (10)	3113-21	2012
Ichikawa T, Taura N, Miyaaki H, Matsuzaki T, Ohtani M, Eguchi S, Takatsuki M, Soyama A, Hidaka M, Okudaira S, Usui T, Mori S, Kamihira S, Kanematsu T, <u>Nakao K.</u>	Human T-cell leukemia virus type 1 infection worsens prognosis of hepatitis C virus-related living donor liver transplantation.	Transpl Int.	25 (4)	433-8	2012
Eguchi S, Hidaka M, Soyama A, Takatsuki M, Miyaaki H, Ichikawa T, <u>Nakao K.</u> , Kanematsu T.	Is liver-targeted FOXP3 staining beneficial after living-donor liver transplantation?	Transpl Infect Dis.	14 (2)	156-62	2012
Yamaguchi T, Ichikawa T, Takeshita S, Taura N, Miyaaki H, Muraoka T, Shibata H, Honda T, Hamasaki K, Kato Y, Takeshima F, <u>Nakao K.</u>	Anti-hepatitis C virus activity of geranylgeranylacetone treatment in hepatitis C-infected patients.	Acta Medica Nagasakiensia.	57 (1)	1-4	2012
Takeshita S, Ichikawa T, Taura N, Miyaaki H, Matsuzaki T, Otani M, Muraoka T, Akiyama M, Miuma S, Ozawa E, Ikeda M, Kato N, Isomoto H, Takeshima F, <u>Nakao K.</u>	Geranylgeranylacetone has anti-hepatitis C virus activity via activation of mTOR in human hepatoma cells.	J Gastroenterol.	47 (2)	195-202	2012
Muraoka T, Ichikawa T, Taura N, Miyaaki H, Takeshita S, Akiyama M, Miuma S, Ozawa E, Isomoto H, Takeshima F, <u>Nakao K.</u>	Insulin-induced mTOR activity exhibits anti-hepatitis C virus activity.	Mol Med Report.	5 (2)	331-5	2012
Kamihira S, Usui T, Ichikawa T, Uno N, Morinaga Y, Mori S, Nagai K, Sasaki D, Hasegawa H, Yanagihara K, Honda T, Yamada Y, Iwanaga M, Kanematsu T, <u>Nakao K.</u>	Paradoxical expression of IL-28B mRNA in peripheral blood in human T-cell leukemia virus type-1 mono-infection and co-infection with hepatitis C virus.	Virol J.	9		2012

Otani M, Honda N, Xia PC, Eguchi K, Ichikawa T, Watanabe T, Yamaguchi K, <u>Nakao K</u> , Yamamoto T.	Distribution of Two Subgroups of Human T-Lymphotropic Virus Type 1 (HTLV-1) in Endemic Japan.	Trop Med Health.	40 (2)	55-8	2012
Taura N, Fukuda S, Ichikawa T, Miyaaki H, Shibata H, Honda T, Yamaguchi T, Kubota Y, Uchida S, Kamo Y, Yoshimura E, Isomoto H, Matsumoto T, Takeshima F, Tsutsumi T, Tsuruta S, <u>Nakao K</u> .	Relationship of α -fetoprotein levels and development of hepatocellular carcinoma in hepatitis C patients with liver cirrhosis.	Exp Ther Med.	4 (6)	972-6	2012
Taura N, Ichikawa T, Miyaaki H, Kadokawa Y, Tsutsumi T, Tsuruta S, Kato Y, Inoue O, Kinoshita N, Ohba K, Kato H, Ohata K, Masuda J, Hamasaki K, <u>Yatsuhashi H</u> , <u>Nakao K</u> .	Baseline serum cholesterol is associated with a response to pegylated interferon alfa-2b and ribavirin therapy for chronic hepatitis C genotype 2.	Gastroenterol Res Pract.			2012
Kondo R, <u>Yano H</u> , Nakashima O, Tanikawa K, Nomura Y, Kage M.	Accumulation of platelets in the liver may be an important contributory factor to thrombocytopenia and liver fibrosis in chronic hepatitis C.	J Gastroenterol.			2012
Torimura T, Ueno T, Taniguchi E, Masuda H, Iwamoto H, Nakamura T, Inoue K, Hashimoto O, Abe M, Koga H, Barresi V, Nakashima E, <u>Yano H</u> , Sata M.	Interaction of endothelial progenitor cells expressing cytosine deaminase in tumor tissues and 5-fluorocytosine administration suppresses growth of 5-fluorouracil-sensitive liver cancer in mice.	Cancer Sci.	103 (3)	542-8	2012
Naito Y, Kusano H, Nakashima O, Sadashima E, Hattori S, Taira T, Kawahara A, Okabe Y, Shimamatsu K, Taguchi J, Momosaki S, Irie K, Yamaguchi R, Yokomizo H, Nagamine M, Fukuda S, Sugiyama S, Nishida N, Higaki K, Yoshitomi M, Yasunaga M, Okuda K, Kinoshita H, Nakayama M, Yasumoto M, Akiba J, Kage M, <u>Yano H</u>	Intraductal neoplasm of the intrahepatic bile duct: clinicopathological study of 24 cases.	World J Gastroenterol.	18 (28)	3673-80	2012
Komuta M, Govaere O, Vandecaveye V, Akiba J, Van Steenberghe W, Verslype C, Laleman W, Pirenne J, Aerts R, <u>Yano H</u> , Nevens F, Topal B, Roskams T.	Histological diversity in cholangiocellular carcinoma reflects the different cholangiocyte phenotypes.	Hepatology	55 (6)	1876-88	2012

Inoue K, Torimura T, Nakamura T, Iwamoto H, Masuda H, Abe M, Hashimoto O, Koga H, Ueno T, <u>Yano H</u> , Sata M.	Vandetanib, an inhibitor of VEGF receptor-2 and EGF receptor, suppresses tumor development and improves prognosis of liver cancer in mice.	Clin Cancer Res.	18 (14)	3924-33	2012
Abe M, Koga H, Yoshida T, Masuda H, Iwamoto H, Sakata M, Hanada S, Nakamura T, Taniguchi E, Kawaguchi T, <u>Yano H</u> , Torimura T, Ueno T, Sata M.	Hepatitis C virus core protein upregulates the expression of vascular endothelial growth factor via the nuclear factor-kappaB/hypoxia-inducible factor-1alpha axis under hypoxic conditions.	Hepatol Res.	42	591-600	2012
Tamada Y, <u>Yatsuhashi H</u> , <u>Masaki N</u> , <u>Nakamuta M</u> , <u>Mita E</u> , <u>Komatsu T</u> , <u>Watanabe Y</u> , <u>Muro T</u> , <u>Shimada M</u> , <u>Hijioka T</u> , <u>Satoh T</u> , Mano Y, <u>Komeda T</u> , Takahashi M, <u>Kohno H</u> , <u>Ota H</u> , Hayashi S, Miyakawa Y, Abiru S, <u>Ishibashi H</u> .	Hepatitis B virus strains of subgenotype A2 with an identical sequence spreading rapidly from the capital region to all over Japan in patients with acute hepatitis B.	Gut.			2012
<u>Yatsuhashi H</u> , Ohnishi Y, Nakayama S, Iwase H, Nakamura T, Imawari M.	Anti-hypoalbuminemic effect of branched-chain amino acid granules in patients with liver cirrhosis is independent of dietary energy and protein intake.	Hepatol Res.	41 (11)	1027-1035	2011
Kurokawa M, Hiramatsu N, Oze T, Yakushijin T, Miyazaki M, Hosui A, Miyagi T, Yoshida Y, Ishida H, Tatsumi T, Kiso S, Kanto T, Kasahara A, Iio S, Doi Y, Yamada A, Oshita M, Kaneko A, Mochizuki K, Hagiwara H, <u>Mita E</u> , Ito T, Inui Y, Katayama K, Yoshihara H, Imai Y, Hayashi E, Hayashi N, Takehara T.	Long-term effect of lamivudine treatment on the incidence of hepatocellular carcinoma in patients with hepatitis B virus infection.	J Gastroenterol.	47(5)	577-85	2012
Oze T, Hiramatsu N, Song C, Yakushijin T, Iio S, Doi Y, Oshita M, Hagiwara H, <u>Mita E</u> , Ito T, Inui Y, <u>Hijioka T</u> , Tamura S, Yoshihara H, Inoue A, Imai Y, Hayashi E, Kato M, Miyazaki M, Hosui A, Miyagi T, Yoshida Y, Tatsumi T, Kiso S, Kanto T, Kasahara A, Hayashi N, Takehara T.	Reducing Peg-IFN doses causes later virologic response or no response in HCV genotype 1 patients treated with Peg-IFN alfa-2b plus ribavirin.	J Gastroenterol.	47(3)	334-342	2012

Kanto T, Inoue M, Oze T, Miyazaki M, Sakakibara M, Kakita N, Matsubara T, Higashitani K, Hagiwara H, Iio S, Katayama K, <u>Mita E</u> , Kasahara A, Hiramatsu N, Takehara T, Hayashi N.	Dynamics of regulatory T cells and plasmacytoid dendritic cells as immune markers for virological response in pegylated interferon- α and ribavirin therapy for chronic hepatitis C patients.	J Gastroenterol.	47(2)	169-178	2012
Hiramatsu N, Inoue Y, Oze T, Kurashige N, Yakushijin T, Mochizuki K, Miyagi T, Tatsumi T, Kiso S, Kanto T, Kasahara A, Takehara T, Oshita M, <u>Mita E</u> , Hagiwara H, Inui Y, Katayama K, Tamura S, Yoshihara H, Imai Y, Hayashi N.	Efficacy of pegylated interferon plus ribavirin combination therapy for hepatitis C patients with normal ALT levels: a matched case-control study.	J Gastroenterol.	46	1335-1343	2011
Oze T, Hiramatsu N, Yakushijin T, Mochizuki K, Imanaka K, Yamada A, Oshita M, Kaneko A, Hagiwara H, <u>Mita E</u> , Ito T, Nagase T, Inui Y, <u>Hijioka T</u> , Tamura S, Yoshihara H, Hayashi E, Imai Y, Kato M, Hosui A, Miyagi T, Yoshida Y, Ishida H, Tatsumi T, Kiso S, Kanto T, Kasahara A, Takehara T, Hayashi N.	Efficacy of re-treatment with pegylated interferon plus ribavirin combination therapy for patients with chronic hepatitis C in Japan.	J Gastroenterol.	46	1031-1037	2011
Oze T, Hiramatsu N, Yakushijin T, Mochizuki K, Oshita M, Hagiwara H, <u>Mita E</u> , Ito T, Fukui H, Inui Y, <u>Hijioka T</u> , Inada M, Kaytayama K, Tamura S, Yoshihara H, Inoue A, Imai Y, Kato M, Miyagi T, Yoshida Y, Tatsumi T, Kiso S, Kanto T, Kasahara A, Takehara T, and Hayashi N.	Indications and limitations for aged patients with chronic hepatitis C in pegylated interferon alfa-2b plus ribavirin combination therapy.	J Hepatol.	54	604-611	2011
Inoue Y, Hiramatsu N, Oze T, Yakushijin T, Mochizuki K, Fukuda K, <u>Mita E</u> , Haruna Y, Inoue A, Imai Y, Hosui A, Miyagi T, Yoshida Y, Tatsumi T, Kiso S, Kanto T, Kasahara A, Takehara T, and Hayashi N.	Amino acid substitution in the core protein has no impact on relapse in hepatitis C genotype 1 patients treated with peginterferon and ribavirin.	J Med Virol.	83	419-427	2011

三田英治	C型肝炎 Hepatitis C among HIV-infected patients.	HIV感染症とAIDSの治療	2 (2)	37-42	2011
H. Kohno, H. Kouno, S. Aimitsu, Y. Aisaka, M. Kitamoto, H. Kawakami, K. Chayama	Impact of ribavirin dose reduction on the efficacy of pegylated interferon plus ribavirin combination therapy for elderly patients infected with genotype 1b and high viral loads.	Hepatol Res.	41	626-634	2011
平嶋 昇, 岩瀬弘明, 都築智之, 神谷麻子, 横井美咲, 斎藤雅之, 玉置 大, 龍華庸光, 日比野佑介, 島田昌明, 後藤秀実	前インターフェロン非治療の1b高ウイルス量C型慢性肝炎に対する二重濾過血漿交換併用ペグインターフェロン・リバビリン療法(第2報).	肝臓	52 (9)	575-583	2011
平嶋 昇, 浦岡正尚, 神谷麻子, 横井美咲, 斎藤雅之, 玉置 大, 龍華庸光, 渡邊久倫, 日比野佑介, 島田昌明, 都築智之, 岩瀬弘明	発症2カ月で慢性肝炎の組織像を呈しインターフェロンで治療したHBV Genotype A急性肝炎の1例.	医療	65 (8)	451-455	2011
Taura N, Ichikawa T, Miyaaki H, Yatsushashi H, Ishibashi H, Nakao K	Prevalence of type 2 diabetes mellitus in Japanese patients with hepatocellular carcinoma.	Exp Ther Med.	2 (1)	81-84	2011
Taura N, Fukushima N, Yatsushashi H, Takami Y, Seike M, Watanabe H, Mizuta T, Sasaki Y, Nagata K, Tabara A, Komorizono Y, Taketomi A, Matsumoto S, Tamai T, Muro T, Nakao K, Fukuizumi K, Maeshiro T, Inoue O, Sata M	The incidence of hepatocellular carcinoma associated with hepatitis C infection decreased in Kyushu area.	Med Sci Monit.	17 (2)	PH7-11	2011
Kawaguchi T, Kakuma T, Yatsushashi H, Watanabe H, Saitsu H, Nakao K, Taketomi A, Ohta S, Tabaru A, Takenaka K, Mizuta T, Nagata K, Komorizono Y, Fukuizumi K, Seike M, Matsumoto S, Maeshiro T, Tsubouchi H, Muro T, Inoue O, Akahoshi M, Sata M	Data mining reveals complex interactions of risk factors and clinical feature profiling associated with the staging of non-hepatitis B virus/non-hepatitis C virus-related hepatocellular carcinoma.	Hepatol Res.	41 (6)	564-571	2011
Miyaaki H, Ichikawa T, Taura N, Miuma S, Shibata H, Isomoto H, Takeshima F, Nakao K	Predictive value of the fibrosis scores in patients with chronic hepatitis C associated with liver fibrosis and metabolic syndrome.	Intern Med.	50 (11)	1137-1141	2011

Hidaka M, Takatsuki M, Soyama A, Miyaaki H, Ichikawa T, <u>Nakao K</u> , Kanematsu T, Eguchi S	Living donor liver transplantation from a donor previously treated with interferon for hepatitis C virus: a case report.	J Med Case Reports.	5	276	2011
Ozawa E, Abiru S, Nagaoka S, Yano K, Komori A, Migita K, <u>Yatsuhashi H</u> , Taura N, Ichikawa T, <u>Ishibashi H</u> , <u>Nakao K</u>	Ferritin/alanine aminotransferase ratio as a possible marker for predicting the prognosis of acute liver injury.	J Gastroenterol Hepatol.	26 (8)	1326-1332	2011
Ichikawa T, Taura N, Miyaaki H, Matsuzaki M, Eguchi S, Takatsuki M, Kanematsu T, <u>Nakao K</u>	Successful pegylated interferon alpha2a monotherapy for hepatitis C virus infection in a transplanted patient who relapsed after the preceding course.	Transpl Infect Dis.	13 (4)	438-440	2011
Miyaaki H, Ichikawa T, Taura N, Miura S, Kawaguchi M, Kohno R, Isomoto H, Takeshima F, Nakashima O, <u>Nakao K</u>	Imaging of focal nodular hyperplastic-like nodules in alcoholic liver cirrhosis patients using gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid magnetic resonance imaging.	Clin J Gastroenterol.	4 (4)	266-272	2011
Honda T, Miyaaki H, Ichikawa T, Taura N, Miura S, Shibata H, Isomoto H, Takeshima F, <u>Nakao K</u>	Clinical characteristics of hepatocellular carcinoma in elderly patients.	Oncol Lett.	2 (5)	851-854	2011
Miyaaki H, Ichikawa T, <u>Yatsuhashi H</u> , Taura N, Miura S, Usui T, Mori S, Kamihira S, Tanaka Y, Mizokami M, <u>Nakao K</u>	Suppressor of cytokine signal 3 and IL28 genetic variation predict the viral response to peginterferon and ribavirin.	Hepatol Res.	41 (12)	1216-1222	2011
Akiba J, Murakami Y, Noda M, Watari K, Ogasawara S, Yoshida T, Kawahara A, Sanada S, Yasumoto M, Yamaguchi R, Kage M, Kuwano M, Ono M, <u>Yano H</u>	N-myc downstream regulated gene1/Cap43 overexpression suppresses tumor growth by hepatic cancer cells through cell cycle arrest at the G0/G1 phase.	Cancer Lett.	310	25-34	2011
Iwamoto H, Torimura T, Nakamura T, Hashimoto O, Inoue K, Kurogi J, Niizeki T, Kuwahara R, Abe M, Koga H, <u>Yano H</u> , Kerbel RS, Ueno T, Sata M	Metronomic S-1 chemotherapy and vandetanib: an efficacious and nontoxic treatment for hepatocellular carcinoma.	Neoplasia	13 (3)	187-197	2011